Oncologia
Câncer de pulmão de não pequenas células metastático não dependente de oncogene: diretriz ESMO para diagnóstico, tratamento e seguimento
23 Jan, 2023 | 13:27h
Estudo randomizado | Adjuvante S-1 comparado com observação no câncer ressecado do trato biliar
23 Jan, 2023 | 13:17hAdjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Comentário no Twitter
New @TheLancet – Nakachi et al – Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial https://t.co/E6y7a9dWNf#gitwitter #biliarytractcancer #onctwitter @OncoAlert #JCOG pic.twitter.com/WEBFXjIWce
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) January 20, 2023
Estudo de braço único fase 2 | Futibatinibe para colangiocarcinoma intra-hepático rearranjado por FGFR2
23 Jan, 2023 | 13:13hFutibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
FGFR2 fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma. In a study, futibatinib, an FGFR inhibitor, induced responses (median, 9.7 months) in 42% of patients. https://t.co/FAXE2AnQ90 pic.twitter.com/9Fn9KxZxeg
— NEJM (@NEJM) January 19, 2023
Estudo de coorte | Hemicolectomia vs. apendicectomia para pacientes com tumores neuroendócrinos do apêndice com 1 a 2 cm de tamanho
23 Jan, 2023 | 13:12hHemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comentário: Appendectomy With or Without Hemicolectomy for 1- to 2-cm Appendiceal Neuroendocrine Tumors – The ASCO Post
Tendências e características das visitas potencialmente evitáveis ao departamento de emergência entre pacientes oncológicos nos EUA
23 Jan, 2023 | 13:02hEditorial: Emergency Department Visits Among Patients With Cancer in the US – JAMA Network Open
Comentário no Twitter
Half of ED visits by patients with cancer are for problems such as pain, fever, vomiting, and infections, and may be preventable with better access to outpatient care. https://t.co/0Yv1ZISrIp @Amir_Alishahi_
— JAMA Network Open (@JAMANetworkOpen) January 19, 2023
Diretrizes ESMO | Tromboembolismo venoso em pacientes com câncer
16 Jan, 2023 | 10:59hVenous thromboembolism in cancer patients: ESMO Clinical Practice Guideline – Annals of Oncology
Conteúdo relacionado: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
Infográfico: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
Consenso | Revisão do sistema de classificação para relatórios sobre biópsias cutâneas de lesões melanocíticas
16 Jan, 2023 | 10:55hComentários:
MPATH-Dx Version 2.0 Simplifies Classification of Melanoma – HealthDay
Comentário no Twitter
American and international #dermatopathologists revise Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis schema. MPATH-Dx V2.0 improves standardized diagnostic reporting and patient management of #melanoma. https://t.co/G0fluzq5fs
— JAMA Network Open (@JAMANetworkOpen) January 12, 2023
Sinopse | Diretrizes da Endocrine Society sobre hipercalcemia em doenças oncológicas
16 Jan, 2023 | 10:53hEndocrine Society Hypercalcemia of Malignancy Guidelines – JAMA Oncology (gratuito por tempo limitado)
Artigo original: Guideline | Treatment of hypercalcemia of malignancy in adults
Estudo randomizado | Radioterapia corpórea estereotáxica guiada por RM vs. guiada por TC para câncer de próstata
16 Jan, 2023 | 10:47hComunicado de imprensa: MRI-guided radiotherapy produces fewer side effects and better quality of life for patients with localized prostate cancer – University of California
Comentário do autor no Twitter (fio – clique para saber mais)
Pleased to share the primary endpoint results of the randomized phase III MIRAGE trial evaluating whether aggressive margin reduction with MRI-guidance leads to reduced toxicity in the context of prostate SBRT, out today in @JAMAOncology https://t.co/5ZKElUR4uk (1/n)
— Amar Kishan (@AmarUKishan) January 12, 2023
Estudo randomizado | Resultados cosméticos e efeitos adversos da irradiação acelerada parcial da mama vs. irradiação completa da mama para carcinoma mamário invasivo de baixo risco
16 Jan, 2023 | 10:39hCosmetic Results and Side Effects of Accelerated Partial-Breast Irradiation Versus Whole-Breast Irradiation for Low-Risk Invasive Carcinoma of the Breast: The Randomized Phase III IRMA Trial – Journal of Clinical Oncology (link para o resumo – $ para o texto completo)
Comentário do autor no Twitter
5yr results of the phase 3 #IRMAtrial: EBRT #APBI b.i.d. associated with slightly increased rate of moderate soft tissue and bone toxicity and a slightly inferior cosmesis, though overall toxicity was in an acceptable range @JCO_ASCO #BCSM @OncoAlert https://t.co/8LHE2ut3t2
— Bruno Meduri (@brunomeduri) January 9, 2023